Targeted Antigens of CAR-T Cell Therapy Information
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T66693 | Target Info | |||
| Target Name | B-cell maturation protein (TNFRSF17) | ||||
| Synonyms | Tumor necrosis factor receptor superfamily member 17; CD269; BCMA; BCM | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | TNFRSF17 | ||||
| UniProt ID | |||||
| Targeted Antigens of CAR-T Cell Therapy | |||||
| CAR T-Cell Therapy Drug(s) | Bb2121 | Drug Info | Phase 2 | Multiple myeloma | [1], [2], [3] |
| Bb2121 | Drug Info | Phase 2 | Multiple myeloma | [4], [5] | |
| LCAR-B38M CAR-T Cell | Drug Info | Phase 2 | Multiple myeloma | [6], [7] | |
| Anti-BCMA CAR-T cells | Drug Info | Phase 1/2 | Multiple myeloma | [8] | |
| Anti-BCMA-CAR-transduced T cells | Drug Info | Phase 1/2 | Multiple myeloma | [9] | |
| AUTO2 | Drug Info | Phase 1/2 | Multiple myeloma | [10] | |
| BCMA CAR T cells | Drug Info | Phase 1/2 | Multiple myeloma | [11] | |
| BCMA CAR-T | Drug Info | Phase 1/2 | Multiple myeloma | [12] | |
| CAR-T cells targeting BCMA | Drug Info | Phase 1/2 | Multiple myeloma | [13] | |
| CART-19/BCMA | Drug Info | Phase 1/2 | Multiple myeloma | [14] | |
| CART-BCMA cells | Drug Info | Phase 1/2 | Multiple myeloma | [15] | |
| CD38 and BCMA CAR-T Cells | Drug Info | Phase 1/2 | Multiple myeloma | [16] | |
| JCARH125 | Drug Info | Phase 1/2 | Multiple myeloma | [17], [18] | |
| JNJ-68284528 | Drug Info | Phase 1/2 | Multiple myeloma | [19] | |
| Anti-BCMA CAR T cells | Drug Info | Phase 1 | Multiple myeloma | [20] | |
| Anti-BCMA CAR T cells | Drug Info | Phase 1 | Multiple myeloma | [21], [22] | |
| Anti-BCMA CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [23] | |
| Anti-BCMA CAR-T cells | Drug Info | Phase 1 | Lymphoma | [24] | |
| Anti-BCMA CART Cells | Drug Info | Phase 1 | Multiple myeloma | [25] | |
| Anti-CD19/BCMA CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [26] | |
| Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 | Drug Info | Phase 1 | Plasma cell myeloma | [27] | |
| Bb21217 | Drug Info | Phase 1 | Multiple myeloma | [28] | |
| BCMA CAR-T Cells | Drug Info | Phase 1 | Multiple myeloma | [29] | |
| BCMA CART | Drug Info | Phase 1 | Multiple myeloma | [30] | |
| BCMA CART and huCART19 | Drug Info | Phase 1 | Multiple myeloma | [30] | |
| BCMA nanobody CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [31] | |
| BCMA-specific CAR-expressing T Lymphocytes | Drug Info | Phase 1 | Plasma cell myeloma | [32] | |
| C-CAR088 | Drug Info | Phase 1 | Multiple myeloma | [33] | |
| CAR-T cells targeting BCMA | Drug Info | Phase 1 | Multiple myeloma | [34] | |
| CART-BCMA | Drug Info | Phase 1 | Multiple myeloma | [35] | |
| Descartes-08 | Drug Info | Phase 1 | Multiple myeloma | [36] | |
| IM21 CART | Drug Info | Phase 1 | Multiple myeloma | [37] | |
| KITE-585 | Drug Info | Phase 1 | Multiple myeloma | [38] | |
| LCAR-B4822M CAR-T Cell | Drug Info | Phase 1 | Multiple myeloma | [39] | |
| P-BCMA-101 | Drug Info | Phase 1 | Multiple myeloma | [40] | |
| P-BCMA-101 CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [41] | |
| BCMA-CART | Drug Info | Clinical trial | Multiple myeloma | [42] | |
| BCMA-UCART | Drug Info | Clinical trial | Multiple myeloma | [43] | |
| CAR-BCMA T cell | Drug Info | Clinical trial | Multiple myeloma | [44] | |
| CAR-T cells targeting BCMA | Drug Info | Clinical trial | Multiple myeloma | [45] | |
| JCARH125 | Drug Info | Clinical trial | Non-hodgkin lymphoma | [17] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02658929) Study of bb2121 in Multiple Myeloma | ||||
| REF 2 | ClinicalTrials.gov (NCT03361748) Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) | ||||
| REF 3 | ClinicalTrials.gov (NCT03601078) An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment | ||||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
| REF 6 | ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | ||||
| REF 7 | ClinicalTrials.gov (NCT03090659) LCAR-B38M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | ||||
| REF 8 | ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | ||||
| REF 9 | ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | ||||
| REF 10 | ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma | ||||
| REF 11 | ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma | ||||
| REF 12 | ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma | ||||
| REF 13 | ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | ||||
| REF 14 | ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT | ||||
| REF 15 | ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma | ||||
| REF 16 | ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | ||||
| REF 17 | ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | ||||
| REF 18 | ClinicalTrials.gov (NCT03430011) Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma | ||||
| REF 19 | ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma | ||||
| REF 20 | ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma | ||||
| REF 21 | ClinicalTrials.gov (NCT02215967) Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | ||||
| REF 22 | ClinicalTrials.gov (NCT03602612) T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | ||||
| REF 23 | ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma | ||||
| REF 24 | ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | ||||
| REF 25 | ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | ||||
| REF 26 | ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | ||||
| REF 27 | ClinicalTrials.gov (NCT03338972) Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma | ||||
| REF 28 | ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma | ||||
| REF 29 | ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma | ||||
| REF 30 | ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma | ||||
| REF 31 | ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma | ||||
| REF 32 | ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma | ||||
| REF 33 | ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | ||||
| REF 34 | ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma | ||||
| REF 35 | ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma | ||||
| REF 36 | ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | ||||
| REF 37 | ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma | ||||
| REF 38 | ClinicalTrials.gov (NCT03318861) A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma | ||||
| REF 39 | ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | ||||
| REF 40 | ClinicalTrials.gov (NCT03741127) Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | ||||
| REF 41 | ClinicalTrials.gov (NCT03288493) P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | ||||
| REF 42 | ClinicalTrials.gov (NCT03492268) Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma | ||||
| REF 43 | ClinicalTrials.gov (NCT03752541) Efficacy and Safety Evaluation of BCMA-UCART | ||||
| REF 44 | ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | ||||
| REF 45 | ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.